RxDoctor Payments Data

Arjun Nanda

Gastroenterology · Palm Harbor, FLNPI 1346539806

Payments from drug & device makers

$9,588in general payments, 2019–2025

Across 518 payments — averaging $18.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$941
  • Johnson & Johnson$788
  • Gilead$635
  • Kerecis Limited$548
  • plus $3K from 30 others

What the payments were for

  • Food & beverage$9,43998%
  • Education$1492%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,588 in reported general payments places this provider in the 70th percentile of 1,388 gastroenterology providers in Florida.

See all gastroenterology providers in Florida

Medicare billing

Part B allowed, 2024
$102,826
Medicare patients
392
Services billed
890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase19$77,060
LinzessLinaclotide29$27,660
SutabSod Sulf/Pot Chloride/Mag Sulf22$3,548
Pantoprazole Sodium204$2,463
Omeprazole164$2,112
CholestyramineCholestyramine (With Sugar)15$1,714
Lubiprostone17$1,379
Dicyclomine Hcl53$955
Tenofovir Disoproxil Fumarate12$700
Colestipol Hcl12$681
Famotidine42$671
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine11$191
Amitriptyline Hcl12$169

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$2,539$104,72048 claims
Braintree Laboratories, Inc.Sutab$25$3,54822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,388 gastroenterology providers in Florida.

Other gastroenterology in Palm Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →